Mergers and Acquisitions

3 Firms Steer Up To $1.95B Alder BioPharmaceuticals Deal

Danish drugmaker Lundbeck on Monday agreed to buy Alder BioPharmaceuticals, which develops treatments for migraines and autoimmune and inflammatory diseases, for as much as $1.95 billion, in a deal driven by Baker McKenzie, Skadden and Cooley. ...read more